ERB-196, also known as WAY-202196, is a synthetic nonsteroidal estrogen that acts as a highly selective agonist of the ERβ.[1][2][3][4][5][6] It possesses 78-fold selectivity for the ERβ over the ERα.[1] The drug was under development by Wyeth for the treatment of inflammation and sepsis starting in 2004 but development was discontinued by 2011.[2][7]
Clinical data | |
---|---|
Other names | WAY-202196 |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C17H10FNO2 |
Molar mass | 279.270 g·mol−1 |
3D model (JSmol) |
|
| |
|